| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.4 |
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.4 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.4 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.055 | 0.4 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | COL-3 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.051 | 0.4 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |